1 / 12

Region II Infertility Prevention Project New York City, New York May 31, 2006

Region II Infertility Prevention Project New York City, New York May 31, 2006. Richard Steece, Ph.D., D(ABMM) National Infertility Prevention Project DrRSteece@aol.com. Region II Infertility Prevention Project New York City, New York May 31, 2006. Supplemental Testing (Repeat Testing)

aricin
Télécharger la présentation

Region II Infertility Prevention Project New York City, New York May 31, 2006

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Region IIInfertility Prevention ProjectNew York City, New YorkMay 31, 2006 Richard Steece, Ph.D., D(ABMM) National Infertility Prevention Project DrRSteece@aol.com

  2. Region IIInfertility Prevention ProjectNew York City, New YorkMay 31, 2006 Supplemental Testing (Repeat Testing) Alternate Specimens (vaginal, rectal and pharyngeal) CDC/APHL 2004 National STD Laboratory Survey

  3. Supplemental Testing • Zanto, et.al.; Region VIII • Gen-Probe ACT and AGC reagents can be used effectively as a supplemental test • Supplemental testing (repeat Gen-Probe AC2) is equally as effective as an alternate target (ACT) • Reporting the initial positive AC2 screening result in this low prevalence (7.5%) population had a greater than 95% positive predictive value (PPV) for CT • Reporting the initial positive AC2 screening result in this low prevalence (1.6%) population had a 91.3% PPV for GC • Based on these PPVs, supplemental or repeat testing need not be routinely performed with NAAT screening, resulting in cost savings.

  4. Alternate Specimens (vaginal, rectal and pharyngeal) • References • California Action Coalition (CAA) • CDC/FDA – Dr. Papp • Workshop NIAID (June 28-29, 2006)

  5. Sexually Transmitted Diseases Laboratory Survey, 2004

  6. Methods: Laboratory Survey • Surveyed 162 public, private and university laboratories in February 2005 • All members of the Association of Public Health Laboratories (APHL) • All laboratories that participate in CDC’s Regional Infertility Prevention Project • An on-line survey was developed that requested the following information for calendar year 2004: • Volume and type of testing for chlamydia and gonorrhea • Volume and type of testing for HSV, Trichomonas, Syphilis, Bacterial Vaginosis, HPV, and Pap Smears

  7. Methods: Laboratory Survey • An e-mail was sent to each laboratory director with link to survey • 34/162 e-mails not successfully transmitted; corrected some addresses and resent. • 25/34 e-mails failed to transmit again; FAXes sent to those lab directors with the link to the survey. • Asked for responses in two weeks • Non-responder follow-up • 2 follow-up e-mails were sent at the end of weeks 1 & 2 • Additional e-mails and phone calls were made after 3 weeks

  8. Results: Laboratory Survey Response • Survey was completed by 119 laboratories (73% response rate) • Responding laboratories were from 49 states and two U.S. territories: • 51% state laboratories (n=61) • 34% county laboratories (n=41) • 10% city laboratories (n=12) • 2% U.S. territory laboratories (n=2) • 2% university laboratories (n=2) • 1% private laboratories (n=1) • Focused on public health laboratories (95% of responding laboratories) • Survey was completed by 114 of 144 public health laboratories (79% response rate)

  9. Testing for Chlamydia and Gonorrhea Public Health Laboratories2000 vs. 2004 Sexually % of Labs that % of all Tests that Transmitted Reported Doing were NAATs Disease NAATs 2000 2004 2000 2004 Chlamydia 58.0 87.0 24.5 63.5 Gonorrhea 38.4 78.7 11.7 60.8

  10. Status of Gonorrhea Culture Public Health Laboratories2000 vs. 2004 Sexually % of Labs that % of all Tests done Transmitted Reported Doing that were Culture Disease GC Culture 2000 2004 2000 2004 Gonorrhea 79.8 77.8 18.0 8.5

  11. Laboratory Survey: Next Steps • Compiled and distributed survey results • Available via the APHL website • Distributed to IPP Coordinators (Word) • Chlamydia and Gonorrhea data was presented in a poster at ISSTDR, July 2005 • Collected information from test kit manufacturers • Number of CT & GC test kits sold in 2004 • % or # sold to public health laboratories • Prepared and submitted manuscript on survey results to JSTD (July)

  12. Male Chlamydia Screening ConsultationMarch 28-29, 2006 • Urine is the specimen of choice when screening males (NAATS) • Leukocyte Esterase Test (LET) is not recommended in any venue. • Pooling should strongly be considered in low prevalence populations (<10%).

More Related